Pure Global
NCT06097962

Safety and Efficacy of NK510 to Treat NSCLC

Exploratory Study of NK510 Combined With PD-1 Blockade in the Treatment of Relapsed and Refractory Advanced NSCLC
Base Therapeutics (Shanghai) Co., Ltd.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
NK510
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Location
Nanjing, China
Timeline & enrollment
Phase
Phase 1
Start date
Jul 01, 2023
End date
Jul 01, 2024
Enrollment
9 participants
Primary outcome

Dose-Limiting Toxicity,Maximal Tolerable Dose

Summary

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and
 refractory advanced NSCLC.NK510 will be administered in combination with PD-1 blockade.
 Patients are required to undergo a biopsy for confirmation of tumor PD-L1 expression,and
 EGFR,ROS1,ALK gene must be negative. The safety and efficacy of this treatment will be
 evaluated.

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06097962
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06097962 through Pure Global AI's free database. This Phase 1 trial is sponsored by Base Therapeutics (Shanghai) Co., Ltd. and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 9 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.